Back to results

Radiation Therapy in Treating Patients With Prostate Cancer

Primary Purpose

Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity

Status

Completed

Phase

Phase 2

Locations

International

Study Type

Interventional

Intervention

36.25 Gy IMRT

51.6 Gy IMRT

About this trial

This is an interventional treatment trial for Prostate Cancer focused on measuring radiation toxicity, sexual dysfunction, psychosocial effects of cancer and its treatment, adenocarcinoma of the prostate, stage I prostate cancer, stage IIA prostate cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

DISEASE CHARACTERISTICS:

Histologically confirmed diagnosis of adenocarcinoma of the prostate within 180 days of randomization
- History/physical examination with digital rectal examination of the prostate within 60 days prior to registration
- Histological evaluation of prostate biopsy with assignment of a Gleason score to the biopsy material; Gleason scores 2-6 within 180 days of randomization
- Clinical stage T1-2a (AJCC 7th edition) within 90 days of randomization
- Prostate-specific antigen (PSA) < 10 ng/mL within 60 days prior to registration;
  - PSA should not be obtained within 10 days after prostate biopsy
No evidence of distant metastases
No regional lymph node involvement

PATIENT CHARACTERISTICS:

Zubrod performance status 0-1
Willingness and ability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire
No prior or concurrent invasive malignancy (except non-melanomatous skin cancer) or lymphomatous/hematogenous malignancy unless continually disease-free for a minimum of 5 years (for example, carcinoma of the oral cavity is permissible; however, patients with prior history of bladder cancer are not allowed)
No severe, active co-morbidity, defined as follows:
- Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
- Transmural myocardial infarction within the last 6 months
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
  - Laboratory tests for liver function and coagulation parameters are not required for entry into this protocol
- Acquired Immune Deficiency Syndrome (AIDS) based upon current Center for Disease Control (CDC) definition
  - HIV testing is not required for entry into this protocol
  - Protocol-specific requirements may also exclude immuno-compromised patients

PRIOR CONCURRENT THERAPY:

No prior radical surgery (prostatectomy), cryosurgery, or high-intensity focused ultrasonography (HIFU) for prostate cancer
No prior pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
No prior hormonal therapy, such as luteinizing hormone-releasing hormone (LHRH) agonists (e.g., goserelin, leuprolide) or LHRH antagonists (e.g., degarelix), anti-androgens (e.g., flutamide, bicalutamide), estrogens (e.g., diethylstilbestrol (DES)), or surgical castration (orchiectomy)
No finasteride within 30 days prior to registration
- Prostate-specific antigen (PSA) should not be obtained prior to 30 days after stopping finasteride
No dutasteride within 90 days prior to registration
- PSA should not be obtained prior to 90 days after stopping dutasteride
No prior or concurrent cytotoxic chemotherapy for prostate cancer
Patients on Coumadin or other blood-thinning agents are eligible for this study
No concurrent 3D-conformal radiation therapy

Sites / Locations

UAB Comprehensive Cancer Center
Arizona Center for Cancer Care - Peoria
Arizona Oncology Services Foundation
Kaiser Permanente - Division of Research - Oakland
Rohnert Park Cancer Center
Kaiser Permanente Medical Center - Roseville
UCSF Helen Diller Family Comprehensive Cancer Center
Kaiser Permanente Santa Clara Medical Center
Kaiser Permanente Medical Center - South San Francisco
Urology Center of Colorado
Emory Crawford Long Hospital
Winship Cancer Institute of Emory University
Queen's Cancer Institute at Queen's Medical Center
Boston University Cancer Research Center
Beth Israel Deaconess Medical Center
Mayo Clinic Cancer Center
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Case Comprehensive Cancer Center
Oklahoma University Cancer Institute
Natalie Warren Bryant Cancer Center at St. Francis Hospital
Rosenfeld Cancer Center at Abington Memorial Hospital
Rothman Specialty Hospital
Fox Chase Cancer Center Buckingham
Academic Urology Prostate Center
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Fox Chase Cancer Center - Philadelphia
Hollings Cancer Center at Medical University of South Carolina
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
University of Virginia Cancer Center
Columbia-Saint Mary's Cancer Care Center
Medical College of Wisconsin Cancer Center
Cross Cancer Institute at University of Alberta
Margaret and Charles Juravinski Cancer Centre
Grand River Regional Cancer Centre at Grand River Hospital
London Regional Cancer Program at London Health Sciences Centre
Hopital Notre-Dame du CHUM

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Arm Label

5 Fractions

12 Fractions

Arm Description

36.25 Gy IMRT in 5 fractions over two and a half weeks

51.6 Gy IMRT in 12 fractions over two and a half weeks

Outcomes

Primary Outcome Measures

Percentage of Patients With Reduction From Baseline to the One-year EPIC Bowel Domain Score That Exceeds 5 Points

The co-primary endpoint is the percentage of patients with a reduction in the Expanded Prostate Cancer Index Composite (EPIC) bowel domain score from baseline to 1 year that exceeds 5 points (baseline - one year > 5). The EPIC is a 50-item, validated tool to assess disease-specific aspects of prostate cancer and its therapies and comprises of four summary domains (bowel, urinary, sexual, and hormonal). Response options for each EPIC item form a Likert scale and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better health related quality of life. Arms are not compared to each other.

The Percentage of Patients With Reduction From Baseline to One-year EPIC Urinary Domain Score That Exceeds 2 Points

The co-primary endpoint is the proportion of patients with a reduction in the Expanded Prostate Cancer Index Composite (EPIC) urinary domain score from baseline to 1 year that exceeds 2 points (baseline - one year > 2). The EPIC is a 50-item, validated tool to assess disease-specific aspects of prostate cancer and its therapies and comprises of four summary domains (bowel, urinary, sexual, and hormonal). Response options for each EPIC item form a Likert scale and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better health related quality of life. Arms are not compared to each other.

Secondary Outcome Measures

Acute and Late Gastrointestinal (GI) and Genitourinary (GU) Toxicity for Each Arm

Adverse events are graded using CTCAE v4.0. Grade refers to the severity of the adverse event (AE). The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. An acute adverse event is defined as the first occurrence of worst severity of the adverse event ≤30 days after the completion of radiation therapy (RT). The high dose RT arm of Radiation Therapy Oncology Group (RTOG) study RTOG-0126 (NCT00033631) reported 1% of patients experienced grade 3+ GI/GU acute toxicity with no patient experiencing a grade 4 or 5 toxicity. If the lower confidence interval is >1%, then that arm will be further investigated for acceptability. A late adverse event is defined as the first occurrence of worst severity of adverse event >30 days after RT completion. Arms are not compared to each other.

Rate of PSA Failure

Failure occurs when the PSA is first noted to be 2 ng/mL or more than the current nadir value (PSA > current nadir + 2) post RT completion. Time to PSA failure is defined as time from registration to the date of PSA failure, last known follow-up (censored), or death without PSA failure (competing risk). Rate of PSA failure is estimated by the cumulative incidence method. The protocol specified that one-, two-, and five-year rates would be reported. Arms are not compared to each other.

Rate of Disease-free Survival (DFS)

Disease-free survival duration is time from the date of randomization to the date of documentation of disease progression or until the date of death from any cause (censored). DFS is estimated by the Kaplan-Meier method. The protocol specified that one-, two-, and five-year rates would be reported. Arms are not compared to each other.

Mean Quality Adjusted Life Years at 5 Years

Quality-adjusted survival time combines disease-free survival time and quality of life as measured by the EuroQol 5-dimensional (EQ-5D) index score. It is calculated for each patient as the weighted sum of different time episodes and added up to total quality-adjusted life years . The EQ-5D measures health-related quality of life and consists of two parts, a general health visual analog scale and 5 general health questions. The latter questions are transformed into a single index score ranging from 0 (worst health state) to 1 (best health state). Arms are not compared to each other.

Change From Baseline in EPIC Bowel and Urinary HRQOL as Continuous Variables at One Year

The EPIC is a 50-item, validated tool to assess disease-specific aspects of prostate cancer and its therapies and comprises of four summary domains (bowel, urinary, sexual, and hormonal). Response options for each EPIC item form a Likert scale and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better health related quality of life and a positive change from baseline indicating improvement over time. For this endpoint, in each domain, the actual change score calculated as timepoint score - baseline score will be used as the statistic.

The Percentage of Patients With Reduction From Baseline at One Year in EPIC Sexual Domain Score That Exceeds 11 Points

The percentage of patients with a reduction in the EPIC sexual domain score from baseline that exceeds 11 points (baseline - one year > 11). The EPIC is a 50-item, validated tool to assess disease-specific aspects of prostate cancer and its therapies and comprises of four summary domains (bowel, urinary, sexual, and hormonal). Response options for each EPIC item form a Likert scale and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better health related quality of life. Arms are not compared to each other.

The Percentage of Patients With Reduction From Baseline at One Year in EPIC Hormonal Domain Score That Exceeds 3 Points

The percentage of patients with a reduction in the EPIC hormonal domain score from baseline that exceeds 3 points (baseline - one year > 3). The EPIC is a 50-item, validated tool to assess disease-specific aspects of prostate cancer and its therapies and comprises of four summary domains (bowel, urinary, sexual, and hormonal). Response options for each EPIC item form a Likert scale and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better health related quality of life. Arms are not compared to each other.

Change From Baseline in EQ-5D Scores

The EQ-5D is a 2-part self-assessment questionnaire. First part is 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 3 problem levels (1-none, 2-moderate, 3-extreme). Health states are defined by the combination of the leveled responses to the 5 dimensions, generating 243 health states to which unconsciousness and death are added. The 2nd part is a visual analogue scale (VAS) valuing current health state, measured on a 20-cm 10-point interval scale. Worst imaginable health state is scored as 0 at the bottom of the scale, and best imaginable health state is scored as 100 at the top. The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state). Change from baseline is calculated as score at the timepoint of interested - baseline score. One, 2, and 5 years will be entered when they are available. Arms are not compared.

Utilization of Sexual Medications/Devices Questionnaire Response Frequences

The Utilization of Sexual Medications/Devices questionaire is designed to assess the use of erectile aids among patients treated for prostate cancer. This instrument is used to complement the sexual symptom domain in the EPIC. The number of subjects responding "Yes" to the following questions are reported: "Do you have a penile prosthesis", "Have you used an medications or devices to aid or improve erections?". Arms are not compared to each other. One, 2, and 5 years will be entered when they are available.

Genetic Markers Associated With Normal Tissue Toxicities Resulting From Radiotherapy

Full Information

NCT ID

NCT01434290

First Posted

September 13, 2011

Last Updated

May 23, 2022

Sponsor

Radiation Therapy Oncology Group

Collaborators

National Cancer Institute (NCI), NRG Oncology

1. Study Identification

Unique Protocol Identification Number

NCT01434290

Brief Title

Radiation Therapy in Treating Patients With Prostate Cancer

Official Title

A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer

Study Type

Interventional

2. Study Status

Record Verification Date

May 2022

Overall Recruitment Status

Completed

Study Start Date

September 2011 (undefined)

Primary Completion Date

June 2015 (Actual)

Study Completion Date

May 20, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Radiation Therapy Oncology Group

Collaborators

National Cancer Institute (NCI), NRG Oncology

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Given radiation therapy in different ways may kill more tumor cells. PURPOSE: This randomized phase II trial studies radiation therapy to see how well it works in treating patients with prostate cancer.

Detailed Description

OBJECTIVES: Primary To demonstrate that 1-year health-related quality of life (HRQOL) for at least one hypofractionated arm is not significantly lower than baseline as measured by the Bowel and Urinary domains of the Expanded Prostate Cancer Index Composite (EPIC) instrument. Secondary To estimate the degree of change in HRQOL in each arm for the Sexual and Hormonal EPIC domains and the Utilization of Sexual Medications/Devices from baseline to 1 year, 2 years, and 5 years. To estimate the degree of change in global HRQOL in each arm as measured by the Euro Quality of Life, 5 dimensions (EQ-5D) from baseline to 1 year, 2 years, and 5 years. To estimate the rate of acute and late gastrointestinal (GI) and genitourinary (GU) toxicity for each arm at 1, 2, and 5 years. To estimate prostate-specific antigen (PSA) failure in each arm at 1, 2, and 5 years. To estimate disease-free survival (DFS) in each arm at 1, 2, and 5 years. To estimate Quality Adjusted Life Years for each arm at 1, 2, and 5 years using the EQ-5D and DFS. To identify genetic markers associated with normal tissue toxicities resulting from radiotherapy. To collect tumor tissue for biomarker studies. To estimate EPIC bowel and urinary HRQOL as continuous variables. OUTLINE: This is a multicenter study. Patients are stratified according to treatment techniques/machine (all linear accelerator-based treatment [excluding cyberknife] vs cyberknife vs protons). Patients are randomized to 1 of 2 treatment arms. Arm I: Patients undergo hypofractionated radiotherapy using intensity-modulated radiation therapy (IMRT), cyberknife, or protons twice a week for approximately 2½ weeks (36.25 Gy total). Arm II: Patients undergo hypofractionated radiotherapy using IMRT, cyberknife, or protons once a day, 5 days a week, for approximately 2½ weeks (51.6 Gy total). Patients may undergo blood and tumor tissue collection for correlative studies. Patients may also complete the Utilization of Sexual Medications/Devices, the European Questionnaire-5D, and the Bowel and Urinary domains of the Expanded Prostate Cancer Index Composite (EPIC) questionnaires at baseline and at 1, 2, and 5 years after completion of radiation therapy. After completion of study therapy, patients are followed-up every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity, Sexual Dysfunction

Keywords

radiation toxicity, sexual dysfunction, psychosocial effects of cancer and its treatment, adenocarcinoma of the prostate, stage I prostate cancer, stage IIA prostate cancer

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Parallel Assignment

Masking

None (Open Label)

Allocation

Randomized

Enrollment

255 (Actual)

8. Arms, Groups, and Interventions

Arm Title

5 Fractions

Arm Type

Experimental

Arm Description

36.25 Gy IMRT in 5 fractions over two and a half weeks

Arm Title

12 Fractions

Arm Type

Experimental

Arm Description

51.6 Gy IMRT in 12 fractions over two and a half weeks

Intervention Type

Radiation

Intervention Name(s)

36.25 Gy IMRT

Intervention Description

36.25 Gy in 5 fractions of 7.5 Gy twice a week over 15-17 days. A minimum of 72 hours and a maximum of 96 hours will separate each treatment. IMRT or similar techniques that use inverse treatment planning or protons are required.

Intervention Type

Radiation

Intervention Name(s)

51.6 Gy IMRT

Intervention Description

51.6 Gy in 12 fractions of 4.3 Gy 5 days a week over 16-18 days. IMRT or similar techniques that use inverse treatment planning or protons are required.

Primary Outcome Measure Information:

Title

Percentage of Patients With Reduction From Baseline to the One-year EPIC Bowel Domain Score That Exceeds 5 Points

Description

Time Frame

Baseline and one year from the end of protocol treatment

Title

The Percentage of Patients With Reduction From Baseline to One-year EPIC Urinary Domain Score That Exceeds 2 Points

Description

Time Frame

Baseline and one year from the end of protocol treatment

Secondary Outcome Measure Information:

Title

Acute and Late Gastrointestinal (GI) and Genitourinary (GU) Toxicity for Each Arm

Description

Time Frame

Start of protocol treatment to one year from the end of protocol treatment

Title

Rate of PSA Failure

Description

Time Frame

Registration to five years

Title

Rate of Disease-free Survival (DFS)

Description

Time Frame

Registration to 5 years

Title

Mean Quality Adjusted Life Years at 5 Years

Description

Time Frame

Registration to 5 years from the end of protocol treatment

Title

Change From Baseline in EPIC Bowel and Urinary HRQOL as Continuous Variables at One Year

Description

Time Frame

Baseline and one year from the end of protocol treatment

Title

The Percentage of Patients With Reduction From Baseline at One Year in EPIC Sexual Domain Score That Exceeds 11 Points

Description

Time Frame

Baseline one year from the end of protocol treatment

Title

The Percentage of Patients With Reduction From Baseline at One Year in EPIC Hormonal Domain Score That Exceeds 3 Points

Description

Time Frame

Baseline and one year from the end of protocol treatment

Title

Change From Baseline in EQ-5D Scores

Description

Time Frame

Baseline and one year from the end of protocol treatment

Title

Utilization of Sexual Medications/Devices Questionnaire Response Frequences

Description

Time Frame

Baseline and one year from the end of protocol treatment

Title

Genetic Markers Associated With Normal Tissue Toxicities Resulting From Radiotherapy

Time Frame

Study entry to 5 years from the end of protocol treatment

10. Eligibility

Sex

Male

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

DISEASE CHARACTERISTICS: Histologically confirmed diagnosis of adenocarcinoma of the prostate within 180 days of randomization History/physical examination with digital rectal examination of the prostate within 60 days prior to registration Histological evaluation of prostate biopsy with assignment of a Gleason score to the biopsy material; Gleason scores 2-6 within 180 days of randomization Clinical stage T1-2a (AJCC 7th edition) within 90 days of randomization Prostate-specific antigen (PSA) < 10 ng/mL within 60 days prior to registration; PSA should not be obtained within 10 days after prostate biopsy No evidence of distant metastases No regional lymph node involvement PATIENT CHARACTERISTICS: Zubrod performance status 0-1 Willingness and ability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire No prior or concurrent invasive malignancy (except non-melanomatous skin cancer) or lymphomatous/hematogenous malignancy unless continually disease-free for a minimum of 5 years (for example, carcinoma of the oral cavity is permissible; however, patients with prior history of bladder cancer are not allowed) No severe, active co-morbidity, defined as follows: Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months Transmural myocardial infarction within the last 6 months Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects Laboratory tests for liver function and coagulation parameters are not required for entry into this protocol Acquired Immune Deficiency Syndrome (AIDS) based upon current Center for Disease Control (CDC) definition HIV testing is not required for entry into this protocol Protocol-specific requirements may also exclude immuno-compromised patients PRIOR CONCURRENT THERAPY: No prior radical surgery (prostatectomy), cryosurgery, or high-intensity focused ultrasonography (HIFU) for prostate cancer No prior pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy No prior hormonal therapy, such as luteinizing hormone-releasing hormone (LHRH) agonists (e.g., goserelin, leuprolide) or LHRH antagonists (e.g., degarelix), anti-androgens (e.g., flutamide, bicalutamide), estrogens (e.g., diethylstilbestrol (DES)), or surgical castration (orchiectomy) No finasteride within 30 days prior to registration Prostate-specific antigen (PSA) should not be obtained prior to 30 days after stopping finasteride No dutasteride within 90 days prior to registration PSA should not be obtained prior to 90 days after stopping dutasteride No prior or concurrent cytotoxic chemotherapy for prostate cancer Patients on Coumadin or other blood-thinning agents are eligible for this study No concurrent 3D-conformal radiation therapy

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Himu R. Lukka, MD

Organizational Affiliation

Margaret and Charles Juravinski Cancer Centre

Official's Role

Principal Investigator

Facility Information:

Facility Name

UAB Comprehensive Cancer Center

City

Birmingham

State/Province

Alabama

ZIP/Postal Code

35294

Country

United States

Facility Name

Arizona Center for Cancer Care - Peoria

City

Peoria

State/Province

Arizona

ZIP/Postal Code

85381

Country

United States

Facility Name

Arizona Oncology Services Foundation

City

Phoenix

State/Province

Arizona

ZIP/Postal Code

85013

Country

United States

Facility Name

Kaiser Permanente - Division of Research - Oakland

City

Oakland

State/Province

California

ZIP/Postal Code

94611

Country

United States

Facility Name

Rohnert Park Cancer Center

City

Rohnert Park

State/Province

California

ZIP/Postal Code

94928

Country

United States

Facility Name

Kaiser Permanente Medical Center - Roseville

City

Roseville

State/Province

California

ZIP/Postal Code

95678

Country

United States

Facility Name

UCSF Helen Diller Family Comprehensive Cancer Center

City

San Francisco

State/Province

California

ZIP/Postal Code

94115

Country

United States

Facility Name

Kaiser Permanente Santa Clara Medical Center

City

Santa Clara

State/Province

California

ZIP/Postal Code

95051

Country

United States

Facility Name

Kaiser Permanente Medical Center - South San Francisco

City

South San Francisco

State/Province

California

ZIP/Postal Code

94080

Country

United States

Facility Name

Urology Center of Colorado

City

Denver

State/Province

Colorado

ZIP/Postal Code

80211

Country

United States

Facility Name

Emory Crawford Long Hospital

City

Atlanta

State/Province

Georgia

ZIP/Postal Code

30308

Country

United States

Facility Name

Winship Cancer Institute of Emory University

City

Atlanta

State/Province

Georgia

ZIP/Postal Code

30322

Country

United States

Facility Name

Queen's Cancer Institute at Queen's Medical Center

City

Honolulu

State/Province

Hawaii

ZIP/Postal Code

96813

Country

United States

Facility Name

Boston University Cancer Research Center

City

Boston

State/Province

Massachusetts

ZIP/Postal Code

02118

Country

United States

Facility Name

Beth Israel Deaconess Medical Center

City

Boston

State/Province

Massachusetts

ZIP/Postal Code

02215

Country

United States

Facility Name

Mayo Clinic Cancer Center

City

Rochester

State/Province

Minnesota

ZIP/Postal Code

55905

Country

United States

Facility Name

Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis

City

Saint Louis

State/Province

Missouri

ZIP/Postal Code

63110

Country

United States

Facility Name

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill

City

Chapel Hill

State/Province

North Carolina

ZIP/Postal Code

27599-7295

Country

United States

Facility Name

Case Comprehensive Cancer Center

City

Cleveland

State/Province

Ohio

ZIP/Postal Code

44106-5065

Country

United States

Facility Name

Oklahoma University Cancer Institute

City

Oklahoma City

State/Province

Oklahoma

ZIP/Postal Code

73104

Country

United States

Facility Name

Natalie Warren Bryant Cancer Center at St. Francis Hospital

City

Tulsa

State/Province

Oklahoma

ZIP/Postal Code

74136

Country

United States

Facility Name

Rosenfeld Cancer Center at Abington Memorial Hospital

City

Abington

State/Province

Pennsylvania

ZIP/Postal Code

19001

Country

United States

Facility Name

Rothman Specialty Hospital

City

Bensalem

State/Province

Pennsylvania

ZIP/Postal Code

19020

Country

United States

Facility Name

Fox Chase Cancer Center Buckingham

City

Furlong

State/Province

Pennsylvania

ZIP/Postal Code

18925

Country

United States

Facility Name

Academic Urology Prostate Center

City

King Of Prussia

State/Province

Pennsylvania

ZIP/Postal Code

19406

Country

United States

Facility Name

Kimmel Cancer Center at Thomas Jefferson University - Philadelphia

City

Philadelphia

State/Province

Pennsylvania

ZIP/Postal Code

19107-5541

Country

United States

Facility Name

Fox Chase Cancer Center - Philadelphia

City

Philadelphia

State/Province

Pennsylvania

ZIP/Postal Code

19111-2497

Country

United States

Facility Name

Hollings Cancer Center at Medical University of South Carolina

City

Charleston

State/Province

South Carolina

ZIP/Postal Code

29425

Country

United States

Facility Name

Gibbs Regional Cancer Center at Spartanburg Regional Medical Center

City

Spartanburg

State/Province

South Carolina

ZIP/Postal Code

29303

Country

United States

Facility Name

University of Virginia Cancer Center

City

Charlottesville

State/Province

Virginia

ZIP/Postal Code

22908

Country

United States

Facility Name

Columbia-Saint Mary's Cancer Care Center

City

Milwaukee

State/Province

Wisconsin

ZIP/Postal Code

53211

Country

United States

Facility Name

Medical College of Wisconsin Cancer Center

City

Milwaukee

State/Province

Wisconsin

ZIP/Postal Code

53226

Country

United States

Facility Name

Cross Cancer Institute at University of Alberta

City

Edmonton

State/Province

Alberta

ZIP/Postal Code

T6G 1Z2

Country

Canada

Facility Name

Margaret and Charles Juravinski Cancer Centre

City

Hamilton

State/Province

Ontario

ZIP/Postal Code

L8V 5C2

Country

Canada

Facility Name

Grand River Regional Cancer Centre at Grand River Hospital

City

Kitchener

State/Province

Ontario

ZIP/Postal Code

N2G 1G3

Country

Canada

Facility Name

London Regional Cancer Program at London Health Sciences Centre

City

London

State/Province

Ontario

ZIP/Postal Code

N6A 4L6

Country

Canada

Facility Name

Hopital Notre-Dame du CHUM

City

Montreal

State/Province

Quebec

ZIP/Postal Code

H2L 4M1

Country

Canada

12. IPD Sharing Statement

Learn more about this trial

Radiation Therapy in Treating Patients With Prostate Cancer

We'll reach out to this number within 24 hrs